Lonza, a CDMO, has signed an agreement to acquire Redberry SAS, a company specializing in rapid microbiology testing solutions using solid-phase cytometry (SPC) technology.

Redberry provides rapid and highly precise microbial detection solutions for the pharmaceutical industry. Its state-of-the-art technology is designed to accelerate microbiology testing, delivering faster and more reliable results to ensure quality control and regulatory compliance.  The Red One System is designed for both rapid sterility and bioburden testing.

Red One rapid sterility testing method

In April 2025, Redberry successfully validated its Red One rapid sterility testing method that delivers results in four days. This solution offers a GMP-compliant alternative to traditional sterility testing, which typically requires a minimum incubation time of 14 days. This improved speed aims to support the pharmaceutical industry’s growing demand for faster product release without compromising safety or regulatory standards.

The acquisition will strengthen Lonza’s testing capabilities with the addition of Redberry’s Red One platform, improving speed and sensitivity in microbial detection, as well as automation to pharmaceutical QC labs. The acquisition will further enhance Lonza’s capabilities for CDMO customers that require rapid and scalable QC solutions for short shelf-life products, reducing time-to-patient.

Mike Goetter, Head of Bioscience, Specialized Modalities, Lonza, said: “By integrating this cutting-edge technology into our portfolio, we are empowering customers with faster and simpler tools that lower compliance costs. It will also support scale-up,  process, and  product  integrity for biologics and cell and gene therapy production. It is a strategic step forward in reducing risk, ensuring right first time delivery, and enhancing efficiency across the industry.”

Jonathan Macron, CEO, Redberry, said: “By combining Red One with Lonza’s global reach and expertise, we will scale our innovation to meet the growing needs of pharmaceutical and industrial manufacturers, accelerate product release and benefit patients worldwide, while together setting a new standard in pharmaceutical quality control.”

The transaction is expected to close in 4Q25, subject to closing conditions.